Introduction
The beta-adrenergic receptor (βAR) family was first described more than 60 years ago (Ahlquist, 1948) and has been since divided into three subtypes: β 1 , β 2 and β 3 (Lands et al., 1967; Emorine et al., 1989) . For the β 3 AR subtype, tissue expression is more restricted compared to β 1 and β 2 , with adipose, heart/vasculature, urinary bladder (mRNA) and ovary (protein) believed to have the highest expression (Thomas and Liggett, 1993; Berkowitz et al., 1995; Uhlen et al., 2015) . In the urinary bladder detrusor muscle of mammals, all three β AR subtypes mRNA are expressed (Nomiya and Yamaguchi, 2003) . Additionally, significant expression of β 3 AR protein is observed in bladder urothelium (Limberg et al., 2010) , the luminal epithelial lining of the urinary bladder (Birder and de Groat, 2007) .
The urinary bladder functions to collect and store urine excreted by the kidneys until voided.
Alternating phases of continence and micturition are controlled by the interplay of the central and peripheral nervous system with the local release of regulatory agents (Andersson and Wein, 2004; Beckel and Holstege, 2011) . Bladder filling occurs by relaxation of the detrusor muscle (via parasympathetic inhibition) with simultaneous contraction of the urethral sphincters to prevent involuntary emptying. It is also thought that release of norepinephrine from the sympathetic hypogastric nerve resulting in activation of primarily β AR receptors enhances bladder compliance via detrusor relaxation, although only sparse sympathetic innervation is observed in the bladder dome (Fowler et al., 2008) . Bladder emptying (so-called micturition) on the other hand occurs via a switch in efferent signaling from sympathetic to parasympathetic, resulting in a release of acetylcholine and to a lesser extent ATP from the pelvic nerve causing detrusor contraction and interruption of release of norepinephrine from the hypogastric nerve This article has not been copyedited and formatted. The final version may differ from this version.
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Page 5 causing urethral sphincter relaxation. Acetylcholine primarily acts on the detrusor via muscarinic M2 and M3 subtypes while ATP acts on P2X-purine receptors, particularly under pathological conditions (Andersson, 2015) , in the detrusor to initiate bladder contraction.
Disruption of this coordinated communication can result in a symptom complex characterized by urinary urgency, with or without urgency-associated urinary incontinence, referred to as overactive bladder (OAB) (Abrams et al., 2002) . It is estimated that 12-23% of the general population exhibits symptoms of OAB, with a significant degradation in quality of life (Irwin et al., 2006; Coyne et al., 2011) . Management of OAB is typically a multimodal approach, employing both non-pharmacological and pharmacological treatment paradigms. When nonpharmacological approaches (i.e. lifestyle and dietary modification) are ineffective, antimuscarinics are the first-line pharmacological treatment, representing the most commonly prescribed drug therapy (Abrams and Andersson, 2007) . Although antimuscarinics have been demonstrated to improve urgency, decrease frequency of micturition and urge incontinence, blockade of the M3 muscarinic receptor can lead to adverse effects (AEs) such as dry mouth and constipation (Abrams and Andersson, 2007) . These AEs contribute to a high discontinuation rate resulting in significant unmet medical need for a pharmacological treatment for OAB with an improved AE profile while maintaining or exceeding the efficacy of antimuscarinics (Chapple et al., 2008) . (Andersson, 1993) . Subsequent studies using selective β 3 AR agonists in isolated human detrusor muscle strips determined that the observed relaxation was due in to activation of β 3 AR (Rouget et al., 2014; Gillespie et al., 2015; Michel and Korstanje, 2016) . Given increasing evidence for β 3 AR activation as a treatment for OAB, efforts to discover or repurpose potent and selective β 3 AR agonists were initiated in recent years (Furuta et al., 2006; Drake, 2008) . Subsequently, four selective β 3 AR agonists, mirabegron (Tyagi and Tyagi, 2010) , ritobegron (Maruyama et al., 2012) , solabegron (Ohlstein et al., 2012) , vibegron (Edmondson et al., 2016) -oxo-4,6,7,8-tetrahydropyrrolo[1,2-α] pyrimidine-6-carboxamide), MRL-037
thiazole-4-carboxamide) were synthesized by the Discovery Chemistry Department (Merck Research Laboratories) as previously described (Moyes et al., 2014; Edmondson et al., 2016; Supplemental Figure S1 ). CL316,243 cold MRL-037 for non-specific binding for 25 min. After incubation, the slides were washed for 4 min with ice-cold binding buffer containing 0.05% TritonX-100 for total of 6 times and then soaked twice into in 30 ml of ice-cold buffer with 0.05% TritonX-100 in a staining jar for 4 min each wash, followed by dipping the slides three times in ice-cold water. Slide were dried and exposed to Kodak MR-2 895 2855 Sigma Kodak® BioMax™ MR film (Cat # Z350400-50EA) for 5 days. Adjacent bladder sections were stained with hematoxylin and eosin for histology following standard protocol (Longnecker, 1966) .
This article has not been copyedited and formatted. The final version may differ from this version. In vitro potency and selectivity of vibegron on β-adrenergic receptors
The ability of vibegron to activate the human, rhesus, rat, and dog β 1 , β 2 and β 3 AR was measured using CHO cell lines stably expressing the appropriate adrenergic receptor (Candelore et al., 1999) . For β 3 AR, the human cell line used expressed β 3 at levels similar to those observed in human detrusor muscle (Supplemental Figure S2) . To quantify the amount of released cAMP following β -AR activation, the LANCE cAMP kit (Perkin Elmer, Shelton, CT) a time-resolved fluorescence resonance energy transfer immunoassay was used. Compounds were serially diluted in DMSO and an aliquot added to either 384-well or 96-well micro titer plates in assay buffer (5mM HEPES, 0.1% BSA in Hank's Balanced Salt Solution). The reaction was initiated by the addition of 6000 cells per well in assay buffer that also contained a cAMP specific antibody labeled with Alexa Fluor 647 and a phosphodiesterase inhibitor (IBMX, Sigma). In order to examine serum-shifted potency, efficacy was evaluated using an assay buffer containing 40% pooled human, rhesus or rat serum. Because of a smaller assay window with serum compared to the buffer assay, the number of cells was increased to 10,000 per well. Following 30-minute incubation at room temperature, the cells were lysed by the addition of LANCE detection buffer containing a europium-labeled cAMP tracer. Fluorescence was measured following one hour incubation at room temperature using a PE Envision reader, exciting at 340nm and measuring emission at 615and 665nm. For each assay, a cAMP standard curve was included and used to convert fluorescence readings directly to cAMP amounts. Values were normalized to a known full agonist (isoproterenol) and the EC 50 and percent maximum activation then determined.
Isometric detrusor muscle tension recordings
This article has not been copyedited and formatted. The final version may differ from this version. Rats were euthanized with CO 2 and the entire bladder was surgically removed and the mucosa was left intact. The bladder was then placed in a bath of Krebs solution (113 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 and 1.5 mM glucose).
The bladder dome was dissected in 4 approximately equal pieces of about 6 mm x 3 mm. Each strip was placed in a warmed (37ºC) organ bath (25 mL) containing oxygenated (95% O 2 + 5%
CO 2 ) Krebs solution. The strips were tied at one end to the organ bath, and connected at the 
Isobologram analysis for assessment of combined drug effects.
Isobologram analysis (Tallarida, 2001 ) was used to determine whether the interactions between a selective β 3 AR agonist CL316,243 and antimuscarinic drugs were additive, synergistic, or antagonistic. CL316,243 was used in this study, as this compound was known to be potent at rat 
Cystometry in rhesus monkeys.
Cystometry was performed as described previously (Nagabukuro et al., 2011) . In brief, rhesus monkeys were anesthetized with an intramuscular injection of Telazol (5 mg/kg) or ketamine HCl (20 mg/kg) followed by intravenous constant rate infusion with ketamine HCl (0.2-0.3 mg/kg/min). Animals were then placed in a supine position and two catheters (20 gauge) were inserted into a saphenous and/or a brachial cephalic vein for compound administration and ketamine infusion/blood sampling, respectively. A triple lumen balloon transurethral catheter and intravesical saline infusion, respectively. The intravesical pressure was recorded using a multiple channel data acquisition system (Power Lab 4/30, AD Instruments, Colorado Springs, CO) at a sampling rate of 20 Hz. After confirming bladder emptiness by ultrasonography, saline was intravesically infused at 15 ml/min. Saline infusion was discontinued when a rapid increase in the intravesical pressure due to the micturition reflex was observed. After two baseline cystometry readings, a compound was intravenously dosed using a rising dose paradigm, with a cystometry measurement performed 10 min after each dose. Blood samples were taken for measurements of plasma compound levels and serum glycerol/free fatty acid (FFA) levels right after each cystometry. The following cystometric parameters were obtained from each cystometry: bladder capacity (duration of bladder filling multiplied by intravesical infusion rate), maximum micturition pressure (the pressure reading of the first peak in intravesical pressure driven by the micturition reflex) and bladder compliance (inverse of average slope of intravesical pressure during filling phase). The changes from baseline were calculated and compared with the values in the vehicle-treated group or baseline values. Compounds were dissolved in sterile 60% PEG400-20% ethanol-20% saline in a volume of 0.2 ml/kg. Serum glycerol levels were determined using commercially available kits (Sigma). Plasma concentrations of compounds were determined by liquid chromatography-tandem mass spectrometry on an Applied
Biosystems API 4000 mass spectrometer. Plasma glycerol and FFA levels were determined using commercially available kits (FG0100, Sigma and NEFA-HR2, Wako, respectively) which rely on a series of enzyme coupled reactions.
Statistical Analysis
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Results

Potency of vibegron at β Adrenergic receptors across species
Vibegron ( Figure 1A ) potently activates human β 3 AR and increases cAMP levels, with an EC 50 of 1.1 nM and 87% activation relative to isoproterenol (Edmondson et al., 2016) . Vibegron is also highly selective over β 1 AR and β 2 AR versus β 3 AR across multiple species, demonstrating >9000-fold selectivity for activation of β 3 AR over β 1 AR or β 2 AR in cell based in vitro functional assays (Table 1) . A small serum shift was observed in the presence of 40% human serum (EC 50
1.7 nM, Figure 1B ). The small effect of serum was also observed for rat and rhesus β 3 AR, consistent with the low non-covalent plasma protein binding (Edmondson et al., 2016) .
Localization of β 3 AR in rhesus bladder with a labeled β 3AR agonist
In order to determine expression of β 3 AR in rhesus tissue, we used a radiolabeled agonist of (Figure 2A ; Supplemental Figure S1 ), a pan-species potent and selective β 3 AR agonist (Moyes et al., 2014) , in tissue autoradiography experiments. This compound is a potent β 3 AR agonist across multiple species with no activity at β 1 or β 2 and with physiochemical properties that make it a suitable tracer for localizing β 3 AR expression in tissue. Similar to the staining pattern in human tissue observed with immunohistochemistry (Limberg et al., 2010) , clear staining of the urothelium was observed in rhesus bladder using [ 3 H]MRL-037 ( Figures 2B   and 2C ). Staining of human bladder tissue with 3 H-MRL-037 produced a similar pattern, albeit with weaker signal than was observed in rhesus (Supplemental Figure S3 ).
Dose Dependent Effects of Vibegron in urodynamic parameters in rhesus monkeys
This article has not been copyedited and formatted. The final version may differ from this version. (vibegron). As in the previous study (Nagabukuro et al., 2011) , vehicle had no statistically significant effect on any of parameters. Vibegron increased bladder capacity in a dose-dependent manner ( Figure 3A) . The maximum bladder capacity increase induced by vibegron was 156% of baseline value, which is comparable to maximum effect with antimuscarinics (Nagabukuro, 2011) . Micturition pressure was significantly decreased at 0.3 and 3 mg/kg ( Figure 3B ). Bladder compliance was increased at doses greater than 0.1 mg/kg ( Figure 3C ). Vibegron also increased serum glycerol and FFA levels in a dose-dependent manner ( Figures 3D and 3E ). Concentration response curves for bladder capacity and serum glycerol closely overlapped (see Table 2 for vibegron plasma levels), where the EC 50 value in increasing bladder capacity was 2.9 nM in total This article has not been copyedited and formatted. The final version may differ from this version. plasma and 1.5 nM at unbound levels; for increasing serum glycerol, the EC 50 value was 9.9 nM in total plasma and 5.0 nM at unbound levels (Edmondson et al., 2016) .
Effect of combined treatments of a β 3 AR agonist with antimuscarinics in isolated detrusor muscle.
CL316,243 and all antimuscarinics oxybutynin, tolterodine and darifenacin, inhibited the EFSinduced isolated detrusor muscle contractions in a concentration-dependent manner ( Figure 4A , B). Unlike oxybutynin, vibegron also depressed the spontaneous contractile activity.
Concentrations that induced 25% inhibition (IC 25 ) were used to determine combination ratios and for isobologram analyses (Table 3) Figure S4 ). Given the potency of methoctramine at muscarinic receptor subtypes other than M2 (Ki, ~1 μM), significant inhibition at the higher concentrations was expected. But at least in the current experimental setting, there were less than 25% inhibition of EFS-induced isolated detrusor contraction. In addition, pretreatment of methoctramine (1 μM) did not affect CL316,243-induced inhibition of detrusor contraction (data not shown). However, methoctramine caused a significant change in isobologram for the darifenacin and CL316,243 combination. As shown in Figure 5D , combination with CL316,243
and darifenacin exhibited much more robust synergism with a pretreatment of methoctramine (CI,
0.16) compared to the same1 μM).
Effect of combined treatments of vibegron and antimuscarinics in rhesus monkeys
To extend our findings of combination therapy with vibegron, co-treatments of vibegron and two antimuscarinic agents tolterodine and darifenacin were evaluated in the cystometry model in rhesus monkeys. We used monotherapy data for tolterodine and darifenacin from our previous publication (Nagabukuro 2011) as we carried out the study with exactly same methods and within similar timeframe. All dose-combinations of vibegron and tolterodine showed a greater bladder capacity increase compared to each compound alone, with effects that are greater than additive at low doses (Table 4 ). In contrast, addition of darifenacin to vibegron induced greater bladder relaxation in rhesus only when used at high doses.
This article has not been copyedited and formatted. The final version may differ from this version. (Limberg et al., 2010) . The potency and selectivity of MRL-037 across several species provides for a unique means to directly compare and quantify β 3 AR expression across multiple species using a single tool. In addition, MRL-037 could be employed to determine ex vivo receptor occupancy, providing a means to directly correlate β 3 AR target engagement in the bladder to efficacy.
We observed staining for β 3 AR in the urothelium of human and rhesus monkey. Given our data, along with previously published observations (Limberg et al., 2010; Kullmann et al., 2011; Otsuka et al., 2013) , β 3 AR is expressed in both the detrusor muscle and bladder urothelium across multiple species. The exact role of β 3 AR in the urothelium and its contribution to the (Masunaga et al., 2010) and Kullmann et al. (Kullmann et al., 2011) showed that in porcine and rat bladder strips relaxation of the detrusor muscle by nonselective β AR and selective β 3 AR stimulation occurs to the same extent with or without urothelium. Alternatively, others reported that the presence of urothelium diminishes nonselective β AR induced relaxation of isolated human detrusor muscle (Otsuka et al., 2008; Propping et al., 2013) . Using subtype selective β AR antagonists, β 2 AR was suggested to be involved in this urothelial effect, whereas β 3 AR directly mediates the relaxation of human detrusor, and its involvement did not differ with or without urothelium (Propping et al., 2013) .
Medicinal chemistry efforts at optimizing the potency, selectivity and pharmacokinetic properties of a series of pyrrolidine derived amides led to the discovery of vibegron which is currently in late stage clinical trials for OAB (Edmondson et al., 2016) . In two different preclinical species, vibegron causes dose-dependent relaxation of urinary bladder, resulting in an increase in bladder capacity and a decrease in micturition pressure. These pharmacodynamic readouts of β 3 AR activation closely overlapping each other. In rats, while decreases in micturition pressure are accompanied by an increase in circulating glycerol levels, we observed elevated glycerol levels in the absence of any effect on bladder compliance suggesting that rat adipose is the more sensitive tissue to β 3 AR activation relative to bladder (Edmondson et al., 2016) . While β 3 AR is also involved in lipolysis in human adipose (Bordicchia eta la., 2014) , the effects of β 3 AR activation in rat adipose appear to be much more profound compared to that observed in human adipose, and this was noted in the early clinical programs looking at β 3 AR agonists for obesity (Ursino et al., 2009) . Chronic administration of β 3 AR agonists in obese rats results in weight loss without changes in food intake due to increased energy expenditures (Ursino et al., 2009; Cernecka et al., 2014) , but no such effect is observed in humans (Arch, 2008) . β 3 AR is the predominant subtype in both white and brown adipose tissue in rats, while in humans and rhesus monkeys only in brown adipose does β 3 AR predominate, with little β 3 AR expression in white adipose (Candelore et al., 1999) . This increased expression of β 3 AR in rat adipose and the more pronounced effect on metabolism may explain our observation of differential sensitivity to β 3 AR agonists in rat adipose versus rat bladder. Alternatively, the difference may not be in tissue sensitivity but may reflect physiological differences in the rodent versus primate lower urinary tract such that β 3 AR agonists may play more active of a role in adipose tissue in rats versus primates.
Our studies combining a β 3 AR agonist with antimuscarinics resulted in enhanced bladder relaxation in both rats and rhesus monkeys, with greater synergism when both muscarinic M2
and M3 subtypes were blocked compared with selective blockade of the M3 subtype. Although M3 appears to be the predominant muscarinic subtype in mediating contractile responses in This article has not been copyedited and formatted. The final version may differ from this version.
jpet.aspetjournals.org Downloaded from bladder detrusor muscle, the role of M2 receptors in bladder is less certain despite it being the more highly expressed subtype (>90% in rat bladder) (Wang et al., 1995) . It has been suggested that the M2 subtype contributes to bladder relaxation but in a more indirect role through the enhancement of M3 mediated contractions and through inhibition of bladder relaxation (Ehlert et al., 2005; Matsumoto et al., 2012) . The inhibition of bladder relaxation mediated by M2
activation is thought to occur via an inhibition of adenylyl cyclase (the M2 receptor subtype is Gi-coupled) which opposes the increase in cAMP elicited by activation of β 3 AR (Matsui et al., 2003; Ehlert et al., 2007) . In the absence of an M2 response, forskolin and isoproterenol exhibit a greater relaxant activity compared to conditions under which M2 is active (Matsui et al., 2003; Ehlert et al., 2007) . Inhibition of M2 activity would have a direct impact on the effects of β 3 AR activation by increasing cAMP levels and would therefore provide greater relaxation mediated through β 3 AR activation, which is in accordance with our findings in this study. Recently, Furuta et al. (Furuta et al., 2016) reported that in conscious female rats, the combination therapy of a β 3 AR agonist and muscarinic M3 antagonists was more effective in increasing bladder capacity than monotherapy and that M2 antagonism had no impact on the effect of a β 3 AR agonist. We also confirmed that simple M2 antagonism did not influence β 3 AR agonist-induced relaxation of rat bladder strips. Additionally, muscarinic receptor subtype contribution to bladder function may differ between species. In non-human primates, muscarinic subtypes other than M3 appear to contribute more to bladder storage functions than rodents (Nagabukuro et al., 2011) . Multiple clinical studies have demonstrated additional benefits by combining solifenacin and mirabegron (Abrams et al., 2015; Kosilov et al., 2015) . Since solifenacin is more M3 selective compared to tolterodine and oxybutynin (Ohtake et al., 2007) , it may be possible to further improve efficacy This article has not been copyedited and formatted. The final version may differ from this version.
jpet.aspetjournals.org Downloaded from at bladder relaxation based on our data suggesting a β 3 AR agonist combined with a non-selective M2/M3 antagonist as the optimal combination therapy in humans.
In conclusion, we have described the pharmacology of a new potent and selective β 3 AR agonist, vibegron, and mechanistic interplay between β 3 AR agonists and muscarinic antagonists in urinary bladder. We have also demonstrated that circulating glycerol and free fatty acid levels could potentially be used as surrogate pharmacodynamic readouts to predict bladder effects of vibegron although care must be exercised when comparing pharmacodynamic effects in different tissue beds (Morgan et al., 2012; Cook et al., 2014) . The potential for β 3 AR agonists as monotherapy to effectively treat OAB has been validated with the recent approval of mirabegron, but given that both muscarinic and β 3 ARs play a critical role in bladder function, additional efficacy (with potential for an improved adverse effects profile) may be achieved by combining standard of care antimuscarinics with β 3 AR agonists. Our observations indicate that combination of β 3 AR agonists with dual M2 and M3 antagonists rather than selective M3 antagonists provides optimal efficacy in the treatment of OAB. Our hypothetical translation to the clinic has yet to be determined, but we propose this potential therapeutic approach to redefine the standard of care for the pharmacological treatment of OAB.
